Advertisement

Molecular Medicine

, Volume 17, Issue 5–6, pp 363–368 | Cite as

Effects of the Histone Deacetylase Inhibitor ITF2357 in Autoinflammatory Syndromes

  • Evelien J Bodar
  • Anna Simon
  • Jos W M van der Meer
Research Article

Abstract

We explored the effects of the oral histone deacetylase (HDAC) Inhibitor ITF2357 In patients with autoinflammatory syndrome. In this prospective open-label pilot study, eight patients were enrolled; one patient with tumor necrosis factor receptor-associated periodic syndrome (TRAPS), three patients with hyper-IgD and periodic fever syndrome (HIDS) and four patients with Schnitzler syndrome were closely followed during 90 d of ITF2357 treatment. Three patients with Schnitzler syndrome and one TRAPS patient experienced a partial remission. In four patients, there was no effect. In HIDS patients, there was a tendency toward a higher attack frequency and increasing attack severity. In two patients (one TRAPS and one HIDS), we observed a decrease of acute-phase response without signs of clinical improvement. One patient with Schnitzler syndrome showed a partial response despite an ongoing acute-phase response. In conclusion, ITF2357 monotherapy was able to induce partial response only in patients with Schnitzler syndrome and no response in patients with HIDS.

Notes

Acknowledgments

Italfarmaco SpA, Cinisello Balsamo (Milano), Italy, prepared the ITF2357 capsules. A Simon received a Netherlands Organisation for Health Research and Development (ZonMW) VENI grant and is now a recipient of a ZonMW VIDI grant.

References

  1. 1.
    McDermott MF, et al. (1999) Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 97:133–4.CrossRefPubMedGoogle Scholar
  2. 2.
    Masters SL, Simon A, Aksentijevich I, Kastner DL. (2009) Horror autoinflammaticus: the molecular pathophysiology of autoinflammatory disease. Annu. Rev. Immunol. 27:621–68.CrossRefPubMedGoogle Scholar
  3. 3.
    de Koning HD, et al. (2006) Beneficial response to anakinra and thalidomide in Schnitzler’s syndrome. Ann. Rheum. Dis. 65:542–4.CrossRefPubMedGoogle Scholar
  4. 4.
    de Koning HD, Bodar EJ, van der Meer JW, Simon A. (2007) Schnitzler syndrome: beyond the case reports: review and follow-up of 94 patients with an emphasis on prognosis and treatment. Semin. Arthritis. Rheum. 37:137–48.CrossRefPubMedGoogle Scholar
  5. 5.
    Drenth JPH, van Deuren M, van der Ven-Jongekrijg J, Schalkwijk CG, van der Meer JWM. (1995) Cytokine activation during attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Blood. 85:3586–93.PubMedGoogle Scholar
  6. 6.
    Frenkel J, et al. (2002) Lack of isoprenoid products raises ex vivo interleukin-1beta secretion in hyperimmunoglobulinemia D and periodic fever syndrome. Arthritis Rheum. 46:2794–803.CrossRefPubMedGoogle Scholar
  7. 7.
    Nowlan ML, et al. (2006) Systemic cytokine levels and the effects of etanercept in TNF receptor-associated periodic syndrome (TRAPS) involving a C33Y mutation in TNFRSF1A. Rheumatology (Oxford). 45:31–7.CrossRefGoogle Scholar
  8. 8.
    Rebelo SL, et al. (2006) Modeling of tumor necrosis factor receptor superfamily 1A mutants associated with tumor necrosis factor receptor-associated periodic syndrome indicates misfolding consistent with abnormal function. Arthritis Rheum. 54:2674–87.CrossRefPubMedGoogle Scholar
  9. 9.
    Aksentijevich I, et al. (2002) De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatalonset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum. 46:3340–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Chae JJ, et al. (2003) Targeted disruption of pyrin, the FMF protein, causes heightened sensitivity to endotoxin and a defect in macrophage apoptosis. Mol. Cell. 11:591–604.CrossRefPubMedGoogle Scholar
  11. 11.
    Cefle A, et al. (2005) A comparison of clinical findings of familial Mediterranean fever patients with and without amyloidosis. Rheumatol. Int. 25:442–6.CrossRefPubMedGoogle Scholar
  12. 12.
    Hull KM, et al. (2002) The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore). 81:349–68.CrossRefGoogle Scholar
  13. 13.
    van der Hilst JC, Simon A, Drenth JP. (2005) Hereditary periodic fever and reactive amyloidosis. Clin. Exp. Med. 5:87–98.CrossRefPubMedGoogle Scholar
  14. 14.
    Bodar EJ, van der Hilst JC, Drenth JP, van der Meer JW, Simon A. (2005) Effect of etanercept and anakinra on inflammatory attacks in the hyper-IgD syndrome: introducing a vaccination provocation model. Neth. J. Med. 63:260–4.PubMedCentralPubMedGoogle Scholar
  15. 15.
    Simon A, et al. (2004) Beneficial response to interleukin 1 receptor antagonist in traps. Am. J. Med. 117:208–10.CrossRefPubMedGoogle Scholar
  16. 16.
    Leoni F, et al. (2005) The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol. Med. 11:1–15.CrossRefPubMedGoogle Scholar
  17. 17.
    Carta S, et al. (2006) Histone deacetylase inhibitors prevent exocytosis of interleukin-1beta-containing secretory lysosomes: role of micro-tubules. Blood. 108:1618–26.CrossRefPubMedGoogle Scholar
  18. 18.
    Simon A, et al. (2004) Simvastatin treatment for inflammatory attacks of the hyperimmunoglobulinemia D and periodic fever syndrome. Clin. Pharmacol. Ther. 75:476–83.CrossRefPubMedGoogle Scholar
  19. 19.
    Furlan A, et al. (2011) Pharmacokinetics, safety and inducible cytokine responses during a phase 1 trial of the oral histone deacetylase inhibitor ITF2357 (givinostat). Mol. Med. 17:353–362.CrossRefPubMedGoogle Scholar
  20. 20.
    Hoffman HM, et al. (2004) Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet. 364:1779–85.CrossRefPubMedGoogle Scholar
  21. 21.
    Vojinovic J, et al. (2011) Safety and efficacy of an oral histone deacetylase inhibitor in systemiconset juvenile idiopathic arthritis. Arthritis Rheum. 63:1452–8.CrossRefPubMedGoogle Scholar
  22. 22.
    Vojinovic J, Damjanov N. (2011) HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis. Mol. Med. 17:397–403.CrossRefPubMedGoogle Scholar

Copyright information

© The Feinstein Institute for Medical Research 2011

Authors and Affiliations

  • Evelien J Bodar
    • 1
  • Anna Simon
    • 1
  • Jos W M van der Meer
    • 1
  1. 1.Department of General Internal Medicine and Nijmegen Institute for Infection, Inflammation, and Immunity (N4i), Internal post 463Radboud University Nijmegen Medical CentreHB Nijmegenthe Netherlands

Personalised recommendations